{"id":4565,"date":"2019-03-28T11:51:51","date_gmt":"2019-03-28T06:21:51","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=4565"},"modified":"2021-07-24T12:57:16","modified_gmt":"2021-07-24T07:27:16","slug":"artificial-intelligence","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/artificial-intelligence","title":{"rendered":"The Business Cocktail"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-69f46158f31bc\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-69f46158f31bc\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/artificial-intelligence\/#Saama_Technologies_raises_USD_40_Million_to_bolster_AI\" >Saama Technologies\nraises USD 40 Million to bolster AI<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/artificial-intelligence\/#FDA_approves_the_first-ever_drug_for_PPD\" >FDA approves the first-ever drug for PPD<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/artificial-intelligence\/#Motif_Bio_issues_share_worth_USD_355_million\" >Motif Bio issues\nshare worth USD 3.55 million<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/artificial-intelligence\/#Novartis_multiple_sclerosis_drug_gets_approval\" >Novartis multiple sclerosis drug gets approval<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.delveinsight.com\/blog\/artificial-intelligence\/#Bammer_Bio_acquires_Thermo_Fisher\" >Bammer Bio acquires\nThermo Fisher<\/a><\/li><\/ul><\/nav><\/div>\n\n<h4 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Saama_Technologies_raises_USD_40_Million_to_bolster_AI\"><\/span><strong>Saama Technologies\nraises USD 40 Million to bolster AI<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p class=\"has-background has-very-light-gray-background-color\"><strong>Saama Technologies <\/strong>has got a hefty investment of <strong>USD 40million<\/strong> to accelerate its<strong> Artificial Intelligence<\/strong> and bolster its use in the branch of Life Sciences. This will help the <strong>California<\/strong> based data analytics company to innovate, curate and accelerate the clinical trials and deliver credible data. <\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"FDA_approves_the_first-ever_drug_for_PPD\"><\/span><strong>FDA approves the first-ever drug for PPD <\/strong><span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p class=\"has-background has-very-light-gray-background-color\">The U.S. <strong>FDA<\/strong> has approved the first-ever drug for treating <strong>postpartum <\/strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/major-depressive-disorder-market\"><strong>depression<\/strong> <\/a>(PPD). The drug <strong>Zulresso (brexanolone)<\/strong> will be injected intravenously (IV) and will be provided through a special program called the <strong>Zulresso REMS Program,<\/strong> which requires the drug to be administered by a health care provider in a certified health care facility.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Motif_Bio_issues_share_worth_USD_355_million\"><\/span><strong>Motif Bio issues\nshare worth USD 3.55 million<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p class=\"has-background has-very-light-gray-background-color\"><strong>Motif Bio, <\/strong>a clinical-stage biopharmaceutical company has raised <strong>USD 3.55 million <\/strong>as <strong>IPO <\/strong>via the issue of 45,000,000 ordinary shares at 6p per Placing Share. The net proceeds will be used for <strong>iclaprim<\/strong> for treating <strong>acute bacterial skin<\/strong> and <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/skin-and-skin-structure-infections-sssi-caused-by-bacteria-pipeline-insight\">skin structure infections<\/a><\/strong>.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Novartis_multiple_sclerosis_drug_gets_approval\"><\/span><strong>Novartis multiple sclerosis drug gets approval <\/strong><span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p class=\"has-background has-very-light-gray-background-color\">The FDA has approved a drug <strong>Mayzent <\/strong>to treat<strong> <\/strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/primary-progressive-multiple-sclerosis-ppms-market\"><strong>Multiple sclerosis<\/strong><\/a><strong>&#8211;<\/strong> the first new one in the last fifteen years. The Swiss drugmaker <strong>Novartis <\/strong>has claimed that drug is the only candidate in the market which has proved itself to be the most effective one in treating <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/secondary-progressive-multiple-sclerosis-spms-market\">secondary progressive MS<\/a><\/strong>. <\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Bammer_Bio_acquires_Thermo_Fisher\"><\/span><strong>Bammer Bio acquires\nThermo Fisher <\/strong><span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p class=\"has-background has-very-light-gray-background-color\">US-based <strong>Brammer Bio <\/strong>has\nbeen acquired by the <strong>Thermo Fisher- <\/strong>a\nlife sciences group. The duo plans to revolutionize and to gain momentum in the\nuse of<strong> Gene therapy <\/strong>to deliver\nbreakthrough drugs. The acquisition will enable <strong>Thermo Fisher <\/strong>to gain an edge in serving biotech customers and <strong>Brammer Bio <\/strong>to<strong> evolve <\/strong>its gene therapies models. <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Saama Technologies raises USD 40 Million to bolster AI Saama Technologies has got a hefty investment of USD 40million to accelerate its Artificial Intelligence and bolster its use in the branch of Life Sciences. This will help the California based data analytics company to innovate, curate and accelerate the clinical trials and deliver credible data. [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":4571,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[17697,3007,1837,704,3005,357,3006,1497,423,2096,2097,3008,2098,3004],"industry":[17225],"therapeutic_areas":[17231,17245],"class_list":["post-4565","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-absssi","tag-acute-bacterial-skin","tag-artificial-intelligence","tag-fda","tag-iclaprim","tag-life-sciences","tag-motif-bio","tag-multiple-sclerosis","tag-novartis","tag-postpartum-depression","tag-ppd","tag-skin-structure-infections","tag-zulresso","tag-zulresso-rems-program","industry-pharmaceutical","therapeutic_areas-infectious-diseases","therapeutic_areas-neurology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Saama Technologies, Motif Bio, Bammer Bio, Novartis in news<\/title>\n<meta name=\"description\" content=\"Saama Technologies has got a hefty investment of USD 40M to accelerate its Artificial Intelligence and bolster its use in the branch of Life Sciences...\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/artificial-intelligence\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Saama Technologies, Motif Bio, Bammer Bio, Novartis in news\" \/>\n<meta property=\"og:description\" content=\"Saama Technologies has got a hefty investment of USD 40M to accelerate its Artificial Intelligence and bolster its use in the branch of Life Sciences...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/artificial-intelligence\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2019-03-28T06:21:51+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-24T07:27:16+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/03\/09021329\/CaptureBusi-4.png\" \/>\n\t<meta property=\"og:image:width\" content=\"657\" \/>\n\t<meta property=\"og:image:height\" content=\"583\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Saama Technologies, Motif Bio, Bammer Bio, Novartis in news","description":"Saama Technologies has got a hefty investment of USD 40M to accelerate its Artificial Intelligence and bolster its use in the branch of Life Sciences...","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/artificial-intelligence","og_locale":"en_US","og_type":"article","og_title":"Saama Technologies, Motif Bio, Bammer Bio, Novartis in news","og_description":"Saama Technologies has got a hefty investment of USD 40M to accelerate its Artificial Intelligence and bolster its use in the branch of Life Sciences...","og_url":"https:\/\/www.delveinsight.com\/blog\/artificial-intelligence","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2019-03-28T06:21:51+00:00","article_modified_time":"2021-07-24T07:27:16+00:00","og_image":[{"width":657,"height":583,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/03\/09021329\/CaptureBusi-4.png","type":"image\/png"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/artificial-intelligence","url":"https:\/\/www.delveinsight.com\/blog\/artificial-intelligence","name":"Saama Technologies, Motif Bio, Bammer Bio, Novartis in news","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/artificial-intelligence#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/artificial-intelligence#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/03\/09021329\/CaptureBusi-4.png","datePublished":"2019-03-28T06:21:51+00:00","dateModified":"2021-07-24T07:27:16+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"Saama Technologies has got a hefty investment of USD 40M to accelerate its Artificial Intelligence and bolster its use in the branch of Life Sciences...","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/artificial-intelligence"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/artificial-intelligence#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/03\/09021329\/CaptureBusi-4.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/03\/09021329\/CaptureBusi-4.png","width":657,"height":583,"caption":"artificial intelligence"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/03\/09021329\/CaptureBusi-4-300x266.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">ABSSSI<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">acute bacterial skin<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">artificial intelligence<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">FDA<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">iclaprim<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Life Sciences<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Motif Bio<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Multiple Sclerosis<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Novartis<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">postpartum depression<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">PPD<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">skin structure infections<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Zulresso<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Zulresso REMS Program<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">ABSSSI<\/span>","<span class=\"advgb-post-tax-term\">acute bacterial skin<\/span>","<span class=\"advgb-post-tax-term\">artificial intelligence<\/span>","<span class=\"advgb-post-tax-term\">FDA<\/span>","<span class=\"advgb-post-tax-term\">iclaprim<\/span>","<span class=\"advgb-post-tax-term\">Life Sciences<\/span>","<span class=\"advgb-post-tax-term\">Motif Bio<\/span>","<span class=\"advgb-post-tax-term\">Multiple Sclerosis<\/span>","<span class=\"advgb-post-tax-term\">Novartis<\/span>","<span class=\"advgb-post-tax-term\">postpartum depression<\/span>","<span class=\"advgb-post-tax-term\">PPD<\/span>","<span class=\"advgb-post-tax-term\">skin structure infections<\/span>","<span class=\"advgb-post-tax-term\">Zulresso<\/span>","<span class=\"advgb-post-tax-term\">Zulresso REMS Program<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 7 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on Mar 28, 2019","modified":"Updated on Jul 24, 2021"},"absolute_dates_time":{"created":"Posted on Mar 28, 2019 11:51 am","modified":"Updated on Jul 24, 2021 12:57 pm"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/4565","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=4565"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/4565\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/4571"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=4565"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=4565"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=4565"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=4565"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=4565"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}